Larger effect sizes in non-randomized studies are associated with higher rates of EMA licensing approval

Evaluate how often the European Medicines Agency (EMA) has authorized drugs based on non-randomized studies and whether there is an association between treatment effects and EMA preference for further testing in RCTs.

Source: Journal of Clinical Epidemiology - February 9, 2018 Category: Epidemiology Authors: Benjamin Djulbegovic, Paul Glasziou, Farina A. Klocksieben, Tea Reljic, Magali VanDenBergh, Rahul Mhaskar, John P.A. Ioannidis, Iain Chalmers Source Type: research